Data availability
The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author.
References
Logue JM, Chavez JC (2021) How to sequence therapies in diffuse large B-cell lymphoma post-CAR-T cell failure. Curr Treat Options Oncol 22(12):112. https://doi.org/10.1007/s11864-021-00906-4
Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X, Li M, Tu H, Liu Y, Tu S, Li Y (2019) Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol 10:2664. https://doi.org/10.3389/fimmu.2019.02664
Di Blasi R, Le Gouill S, Bachy E, Cartron G, Beauvais D, Le Bras F, Gros FX, Choquet S, Bories P, Feugier P, Casasnovas O, Bay JO, Mohty M, Joris M, Gastinne T, Sesques P, Tudesq JJ, Vercellino L, Morschhauser F, Gat E, Broussais F, Houot R, Thieblemont C (2022) Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. Blood 140(24):2584–2593. https://doi.org/10.1182/blood.2022016945
Spiegel JY, Dahiya S, Jain MD, Tamaresis J, Nastoupil LJ, Jacobs MT, Ghobadi A, Lin Y, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Goy A, Vu K, Andreadis C, Munoz J, Bennani NN, Vose JM, Dorritie KA, Neelapu SS, Locke FL, Rapoport AP, Hill BT, Miklos DB (2021) Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood 137(13):1832–1835. https://doi.org/10.1182/blood.2020006245
Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR (2023) Smart start: rituximab, lenalidomide, and ibrutinib in patients with newly diagnosed large B-cell lymphoma. J Clin Oncol 41(4):745–755. https://doi.org/10.1200/JCO.22.00597
Westin J (2019) Ibrutinib and lenalidomide: when 1+1 = >2. Blood 134(13):996–998. https://doi.org/10.1182/blood.2019002237
Goy A, Ramchandren R, Ghosh N, Munoz J, Morgan DS, Dang NH, Knapp M, Delioukina M, Kingsley E, Ping J, Beaupre DM, Neuenburg JK, Ruan J (2019) Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL. Blood 134(13):1024–1036. https://doi.org/10.1182/blood.2018891598
Ramchandren R, Johnson P, Ghosh N, Ruan J, Ardeshna KM, Johnson R, Verhoef G, Cunningham D, de Vos S, Kassam S, Fayad L, Radford J, Bailly S, Offner F, Morgan D, Munoz J, Ping J, Szafer-Glusman E, Eckert K, Neuenburg JK, Goy A (2023) The iR(2) regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study. EClinicalMedicine 56:101779. https://doi.org/10.1016/j.eclinm.2022.101779
Acknowledgements
We thank the patient for allowing us to report his case and acknowledged the support of nurses and laboratory scientists who had participated in the process of diagnosis and treatment.
Funding
This work was supported by a grant from the National Natural Science Foundation of China (No. 82072927).
Author information
Authors and Affiliations
Contributions
CL, XZ, DZ, and XB collected, verified, and interpreted patient information and drafted the manuscript. PZ and LW designed the research and critically reviewed and revised the final draft. All authors approved the submitted version of the paper.
Corresponding authors
Ethics declarations
Ethics approval
Written informed consent was obtained from the patient for the publication of any potentially identifiable images or data included in this article.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Li, C., Zhang, X., Zhu, D. et al. Ibrutinib plus rituximab and lenalidomide for primary intestinal diffuse large B-cell lymphoma relapsed after anti-CD19 CAR-T cell therapy: a case report. Ann Hematol 102, 3625–3627 (2023). https://doi.org/10.1007/s00277-023-05421-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-023-05421-0